Cronos Australia (CAU.AX)

Overall impact
C (41)

Commentary

Cronos Australia is an average overall performer. With a 'C' rating of 41.4 for overall impact (26th percentile compared to all companies), Cronos Australia ranks 246th out of 254 industry peers, behind Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 242 others, and ahead of Perrigo, Viatris, Padagis and 5 others. On top material causes for Cronos Australia's industry (Pharmaceuticals), Cronos Australia performs well in Child and Maternal Health (95.0 score), Child and Maternal Health (95.0), Child and Maternal Health (95.0) and 57 other causes where it received an 'A' score and performs poorly in Accountable Institutions (22.5 score), Reduced Inequality (9.4), Accountable Institutions (3.8) and 45 other causes where it received a 'D' or 'F' score.
Screens
Fur
Impact
Cause CAU.AX
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2016
Employees
8
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Vic, Australia
Share classes
CAU.AX
Description
Cronos Australia Limited engages in the sale and distribution of medicinal cannabis products, and operation of medicinal cannabis clinic businesses in Australia and Asia. It operates through three segments: Medical, Clinics, and Consumer. The company sells its medicinal cannabis products under the Adaya brand, as well as through online marketplace platform. It also offers hemp seed oil personal care consumer products under the Bathing Shed brand; and CBD-based products under the FCTR and Saiph brands. The company was incorporated in 2018 and is based in South Yarra, Australia.
Material causes
Ethos considers the following causes material for Cronos Australia, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.